Android app on Google Play

Aegis Capital Lifts PT on Oramed Pharma (ORMP) to $30 Ahead of ORMD-0801 Phase 2a Data

January 8, 2014 9:20 AM EST Send to a Friend
Get Alerts ORMP Hot Sheet
Price: $10.14 +5.41%

Rating Summary:
    2 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 3 | Down: 4 | New: 7
Trade ORMP Now!
Join SI Premium – FREE
Aegis Capital boosts its price target on Oramed Pharmaceuticals, Inc. (Nasdaq: ORMP) from $25 to $30, while maintaining its Buy rating.

Analyst Ram Selvaraju noted that, following recent rounds of equity raising, the company has about $20 million of pro forma cash and is well-prepared to advance clinical initiatives through the end of 2015.

Selvaraju also commented that positive proof-of-concept data has been generated in animals for both ORMD-0801, its oral insulin candidate, as well as ORMD-0901, its oral exenatide drug candidate. Early-stage human data for ORMD-0801 has also been promising. He sees data from ORMD-0801 Phase 2a being released within a few weeks. The analyst said, While this trial is of too short a duration to provide a clear indication of the magnitude of efficacy, positive results in this study could pave the way for a Phase 2b trial of ORMD-0801. Positive Phase 2b data could set the scene for a transformative licensing transaction or an acquisition of Oramed by an established diabetesfocused firm like AstraZeneca, Novartis (NYSE: NVS), Novo Nordisk (NYSE: NVO), or Sanofi S.A. (NYSE: SNY).

For an analyst ratings summary and ratings history on Oramed Pharma click here. For more ratings news on Oramed Pharma click here.

Shares of Oramed Pharma closed at $18.76 yesterday, with a 52 week range of $0.31 to $19.29.




You May Also Be Interested In


Related Categories

Analyst Comments, Analyst PT Change, FDA

Related Entities

Definitive Agreement

Add Your Comment